Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Explainers
The 100 best performing ASX stocks in FY20
Experts
Scopo’s health powerplays: Get ready for the pullback
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
Check up: Sometimes no news is good news
Health & Biotech
What’s Opthea eyeing now that it has two successful trials under its belt?
Health & Biotech
Opthea’s done it again: Its drug passed its DME clinical trial
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Clock’s Ticking: In 24 hours we’ll know if Opthea’s DME clinical trial was successful
Experts
Scopo’s health powerplays: You’re all going to the pot, literally
Health & Biotech
We’re still here: investors keen on health despite market shun
Health & Biotech
TGA says no to 13 eye drugs, elderly still waiting for something that works
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
Health & Biotech
Flying or Falling: Are 2019’s top 5 health stocks still racing ahead this year?
Health & Biotech
Cellmid shares jump after securing deal on Chinese COVID-19 testing kits
News
Trading Places: The stocks the money managers are buying (and selling)
News
The curious case of the vanishing female executive
Health & Biotech